Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

Reichardt, P.; Demetri, G.D.; Gelderblom, H.; Rutkowski, P.; S.A. im; Gupta, S.; ... ; Heinrich, M.C. (2016)

Article / Letter to editor

• Sunitinib
• Imatinib
• GIST
• KIT
• KIT mutation
• Imatinib-resistant GIST
• Overall survival
• Progression-free survival

• All authors: Reichardt, P.; Demetri, G.D.; Gelderblom, H.; Rutkowski, P.; S.A. im; Gupta, S.; Kang, Y.K.; Schoffski, P.; Schuette, J.; Soulieres, D.; Blay, J.Y.; Goldstein, D.; Fly, K.; Huang, X.; Corsaro, M.; Lechuga, M.J.; Martini, J.F.; Heinrich, M.C.
• Date: 2016-01-15
• Journal: BMC Cancer
• Volume: 16
• DOI: doi:10.1186/s12885-016-2051-5